Considerations for the Care and Treatment of Mental and Substance Use Disorders in the COVID-19 Epidemic
https://www.samhsa.gov/sites/default/files/considerations-care-treatment-mental-substance-use-disorders-covid19.pdf
Considerations for Crisis Centers and Clinicians in Managing the Treatment of Alcohol or Benzodiazepine Withdrawal during the COVID-19 Epidemic: March 19, 2020
https://www.samhsa.gov/sites/default/files/considerations-crisis-centers-clinicians-treatment-alcohol-benzodiazepine-withdrawal.pdf
Considerations for Outpatient Mental and Substance Use Disorder Treatment Settings
https://www.samhsa.gov/sites/default/files/considerations-outpatient-mental-substance-use-disorder-treatment-settings.pdf
Opioid Treatment Program (OTP) Guidance
https://www.samhsa.gov/sites/default/files/otp-guidance-20200316.pdf
OTP Guidance for Patients Quarantined at Home with the Coronavirus
https://www.samhsa.gov/sites/default/files/otp-covid-implementation-guidance.pdf
FAQs: Provision of methadone and buprenorphine for the treatment of Opioid Use Disorder in the COVID-19 emergency
https://www.samhsa.gov/sites/default/files/faqs-for-oud-prescribing-and-dispensing.pdf
COVID-19 and Opioid Treatment Programs
https://www.samhsa.gov/sites/default/files/sample-otp-covid-19-faqs.pdf
US Department of Justice
https://www.deadiversion.usdoj.gov/GDP/(DEA-DC-022)(DEA068)%20DEA%20SAMHSA%20buprenorphine%20telemedicine%20%20(Final)%20+Esign.pdf
OCR Announces Notification of Enforcement Discretion for Telehealth Remote Communications During the COVID-19 Nationwide Public Health Emergency
https://www.hhs.gov/about/news/2020/03/17/ocr-announces-notification-of-enforcement-discretion-for-telehealth-remote-communications-during-the-covid-19.html
DEA COVID-19 Information Page
https://www.deadiversion.usdoj.gov/coronavirus.html
Synar letter SSAS Covid
https://www.samhsa.gov/sites/default/files/synar-letter-ssas-covid.pdf
